DigitalDx Ventures

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Biotia, Inc. is a health tech company based in New York, founded in 2016. It specializes in developing software and laboratory technology that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery. Biotia's solutions focus on microbial surveillance and tailored sequencing to reduce hospital-acquired infections. By enabling clinicians and researchers to identify and stop pathogens before patients fall ill, Biotia aims to improve patient treatment and health outcomes, thereby contributing to safer healthcare environments.

GLX Analytix is a biotechnology company focused on advancing personalized medicine through a proprietary class of blood biomarkers combined with artificial intelligence. The company specializes in early diagnosis and monitoring of chronic diseases, providing clinicians with tools to track disease progression, monitor treatment responses, and predict flare-ups. By enhancing patient empowerment and enabling self-monitoring, GLX Analytix aims to optimize treatment plans and improve health outcomes. The company collaborates with institutions like Harvard Medical / Wyss Diagnostic Accelerator and has received recognition for its innovative approach, highlighting its potential to significantly impact patient lives globally.

Trayt, Inc. is a patient-centric data analytics company that specializes in developing tools for measuring the efficacy of treatments for patients with neuropsychiatric conditions. Established in 2013 and based in Redwood City, California, Trayt provides enterprise software designed for the healthcare sector, enabling physicians, therapists, and other care providers to track, measure, and share behavioral and medical outcomes. The company's platform collects and evaluates symptoms and health factors, delivering real-time clinical insights that enhance diagnostic and treatment accuracy, as well as care coordination. Through its innovative approach, Trayt aims to improve the overall quality of care for patients with brain-based disorders.

Optina Diagnostics Inc. is a diagnostics company based in Montréal, Canada, founded in 2010. It specializes in the early detection of Alzheimer's disease through innovative hyperspectral imaging technology that examines the retina. By employing non-invasive diagnostic tests, Optina Diagnostics identifies key biomarkers, such as beta-amyloid plaques, which are crucial for assessing patients' health and disease risk. The company's advanced imaging systems also aid in the detection of age-related macular degeneration and ocular diabetic retinopathy, providing physicians with critical information that enables timely and appropriate patient care. Through its focus on retinal features and artificial intelligence, Optina Diagnostics aims to transform the assessment of brain health and address under-diagnosed diseases.

NephroSant is a diagnostic startup founded by physicians and supported by a team of scientists, engineers, and clinicians. The company focuses on developing a urine-based diagnostic tool that aims to predict and prevent the progression of kidney disease. This innovative tool allows for the quantitative measurement of biomarkers, facilitating the early detection and ongoing monitoring of kidney health. It is particularly beneficial for physicians, as it enables the noninvasive detection of acute rejection in kidney transplant patients, ultimately contributing to improved outcomes in kidney care.

Trayt, Inc. is a patient-centric data analytics company that specializes in developing tools for measuring the efficacy of treatments for patients with neuropsychiatric conditions. Established in 2013 and based in Redwood City, California, Trayt provides enterprise software designed for the healthcare sector, enabling physicians, therapists, and other care providers to track, measure, and share behavioral and medical outcomes. The company's platform collects and evaluates symptoms and health factors, delivering real-time clinical insights that enhance diagnostic and treatment accuracy, as well as care coordination. Through its innovative approach, Trayt aims to improve the overall quality of care for patients with brain-based disorders.

Delphi Diagnostics is a biotechnology company focused on diagnosing breast cancer. The company specializes in a gene expression interpretive algorithm that assesses the sensitivity of patients with hormone receptor positive HER2 negative breast cancer to endocrine therapy. By providing diagnostic and predictive testing processes, Delphi Diagnostics aims to help patients, clinicians, and healthcare systems enhance disease-free survival rates, reduce treatment toxicity, and avoid unnecessary therapies. This approach is designed to improve overall treatment outcomes for individuals affected by breast cancer.

AEENA Dx is focused on creating a saliva-based diagnostic platform aimed at improving the detection of cancer and other diseases. The company is particularly dedicated to developing biofluid-based molecular diagnostic tests that enhance the accuracy, accessibility, and affordability of breast cancer detection for women. By offering innovative testing solutions, AEENA Dx aims to improve the sensitivity and specificity of traditional mammography programs, making it easier for patients to identify breast cancer early and take necessary preventive measures.

Optina Diagnostics Inc. is a diagnostics company based in Montréal, Canada, founded in 2010. It specializes in the early detection of Alzheimer's disease through innovative hyperspectral imaging technology that examines the retina. By employing non-invasive diagnostic tests, Optina Diagnostics identifies key biomarkers, such as beta-amyloid plaques, which are crucial for assessing patients' health and disease risk. The company's advanced imaging systems also aid in the detection of age-related macular degeneration and ocular diabetic retinopathy, providing physicians with critical information that enables timely and appropriate patient care. Through its focus on retinal features and artificial intelligence, Optina Diagnostics aims to transform the assessment of brain health and address under-diagnosed diseases.